Literature DB >> 35579228

Polisomographic Investigation of Sleep Disorders in Patients with Sickle Cell Anemia and Evaluation of the Effect on the Prognosis.

Nursel Dikmen1, Emine Esra Okuyucu2, Murat Güntel2, Edip Uçar3, Gül İlhan4, Cenk Babayiğit1, Mehmet Karadağ5.   

Abstract

Entities:  

Year:  2022        PMID: 35579228      PMCID: PMC9450050          DOI: 10.5152/TurkThoracJ.2022.21199

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


× No keyword cloud information.
Obstructive sleep apnea syndrome (OSAS) is a disease that causes serious mortality and morbidity. The presence of concomitant OSAS in sickle cell patients has negative effects on the prognosis of the disease. Therefore, OSAS symptoms should be questioned in sickle cell patients, suspicious patients should be evaluated with polysomnography, and patients with OSAS should be treated.

Introduction

Sickle cell anemia caused by sickle cell disease (SCD) is one of the most common hemoglobinopathies in the world. The replacement of glutamic acid with valine at the 6th position of the β globin chain results in hemoglobin S (Hb S), an abnormal hemoglobin (Hb). It shows autosomal recessive inheritance.[1] Sickle cell disease is characterized by complications associated with chronic hemolytic anemia and recurrent vaso-occlusion of small vessels. One of the strongest triggers for vaso-occlusion is hemoglobin oxygen (HbO2) desaturation. Hemoglobin oxygen desaturation has been associated with various complications in SCD, including increased pain (especially prominent in the extremities), central nervous system events (stroke, etc.), cognitive dysfunction, and acute chest syndrome.[2] Individuals with homozygous variant S alleles or Hb SS (SS) disease develop serious complications such as chronic hemolysis syndrome, pulmonary hypertension, and stroke together with anemia.[3] Obstructive sleep apnea syndrome (OSAS) is a complete and/or partial airway obstruction that can cause significant physiological discomfort with various clinical effects. Etiology is multifactorial and clinical symptoms are snoring, morning headaches, daytime sleepiness, and impairment in cognitive performance. Some recent international studies show that the prevalence of OSAS is 2%-4% in men and 1%-2% in women.[4] Since HbO2 desaturation frequently occurs in patients with OSA, recent research has focused on the relationship between SCD and OSA.[1] The aim of this study is to investigate the prevalence of sleep disturbance and its effect on the prognosis of the disease in SCD patients.

Material and Methods

Forty-nine patients over the age of 18 who were followed up by the hematology department for Hb SS disease (SCD), who did not have any active symptoms, and did not describe acute painful crisis or acute chest syndrome were included in the study. Detailed anamnesis of the patients were taken. Demographic data (height, age, weight, medications, duration of illness, etc.) were recorded. Hemoglobin, hematocrit, and ferritin results from the routine blood tests of the patients were recorded. Patients were subjected to polysomnographic examination after a detailed sleep questioning (Epworth Sleepiness Scale (ESS), Stanfort Sleepiness Scale, and the berlin questionnaire). Physical examination findings and mallampati scores were recorded. Emergency service admissions of SCD patients in the last 1 year and the history of hospitalization due to painful crisis and/or acute chest syndrome in the last 1 year were questioned. Patients under 18 years of age, patients with known sleep problems other than SCD, additional systemic disease, known respiratory disease, and patients who did not consent to polysomnographic evaluation were excluded from the study. A total of 28 SCD patients were included in the study. All patients included in the study underwent polysomnography, regardless of their symptoms As the control group, 30 healthy volunteers over the age of 18, who had no known disease, and who had similar demographic data to the SCD group were included in the study. Consent was obtained from the volunteer patients. A control group was formed with a total of 22 volunteers, whose consents were obtained and accepted for the polysomnographic examination. Detailed anamnesis was taken and physical examination findings were recorded. Pulmonary function tests were performed in both groups if there were no contraindications (having recently had Myocardial Infarction (MI) known thoracic abdominal or cerebral aneurysm, having recently had eye surgery, etc.) after respiratory system examination, and the results were recorded. Confirmation of the Local Ethics Committee was obtained. Our study was approved by Hatay Mustafa Kemal University, Ethics Committee with the date and number of 2018/36. The purpose of our study was explained to the participants in detail, and informed by Helsinki rules, and a consent form was obtained. The patients were informed about what procedures would be applied, and they completed filling out the informed consent forms. Each patient was interviewed after the polysmonography test, and demographic data of the patients, height, and weight measurements were recorded. Similar numbers of patients were included in both groups. Patients were questioned with regards to age, gender, associated additional diseases, existing symptoms and risk factors, smoking habits, and alcohol use. Age, gender, height, and weight values of the patients were noted, and body mass indices (BMI) were calculated (BMI = weight/height²) (kg/m²). Epworth Sleepiness Scale was completed for each patient. The ESS is a test used to demonstrate daytime sleepiness. It consists of 8 questions in total. Each question is filled by the patient himself/herself to give 0-3 points. In this survey, the possibility of falling asleep in certain situations is questioned on an ordinary day when the patient is not overly tired. Total scores of the patients were recorded. If the total score is 10 or more, it indicates the presence of excessive daytime sleepiness. The validity and reliability of the ESS in terms of excessive daytime sleepiness have been demonstrated by domestic and international studies. In addition, patients were evaluated in terms of restless leg syndrome (RLS). The diagnosis of RLS was made using the criteria of the International Restless Legs Syndrome Study Group (IRLSSG). The patients were asked 4 questions to identify RLS and those who answered yes were accepted as having RLS.[5] For the severity of RLS, the IRLS Rating Scale was used. The IRLS Rating Scale is a scale on typical symptoms of the disease, each of which is graded from 0 to 4. The evaluation is made with this scale as follows: 0-10 points were evaluated as mild, 11-20 points as moderate, 21-30 points as severe, and 31-40 points as very severe RLS.[6] Two subjective scales and polysomnographic objective evaluation are used to measure RLS severity. Another subjective scale is the Johns Hopkins RLS severity scale (JHRLSS) and it was developed to evaluate the current status of patients before treatment. Patients are graded according to the time of onset of symptoms with this scale. It is scored between 0 and 3 (Table 1).[7] In addition to patients with RLS symptoms, we applied the JHRLSS.
Table 1.

John Hopkins Scale

ScoreHours of RLS Symptoms Beginning
0 (Never) No symptoms
1 (Mild) At bedtime and/or during the sleep period (symptoms may occur within 60 minutes before the usual bed or simply at the time of going to bed or during the night after bed).
2 (Moderate) At Night (6 pm and after)
3 (Severe) In the afternoon (before 6 pm). Symptoms may begin in the afternoon or last all day.

Polysomnography

Standard polysomnography was performed for all patients overnight. Philips Respironics, ALIS 6 LDXN, 68 channel polysomnography, Sleepware G3 (USA) device was used for poisomnographic evaluation. Measurements performed during polysomnography (PSG) testing were 4 channel electroencephalograpy (C3-A2, C4-A1, O1-A2, and 02-A1), 2 channel electrooculogram, electrocardiogram, electromyogram monitoring (submental and tibialis anterior muscle), oronasal airflow and nasal airflow, thoracoabdominal movements, and oxygen saturation with fingertip pulse oximeter. Video and audio recordings as well as body position were obtained. Sleep scoring was conducted according to the criteria of Rechtschaffen and Kales.[8] All respiratory events were scored simultaneously by 2 physicians with experience and certification in sleep medicine, according to the guidelines of the American Academy of Sleep Medicine.[9] A decrease of more than 90% in airflow for at least 10 seconds was considered as apnea. If respiratory effort is recorded throughout the event, it was evaluated as obstructive apnea. If respiratory effort is absent throughout the event, it was evaluated as central apnea. If there is absence of respiratory effort at the beginning of the event followed by increasing respiratory effort during the second half, it was evaluated as mixed apnea. Thoracic and abdominal movements were accepted as respiratory efforts. A 50% decrease in air flow for at least 10 seconds and a decrease in saturation of at least 3% were accepted as hypopnea. Obstructive sleep apnea syndrome was diagnosed based on the International Classification of Sleep Disorders-3 classification and defined as the presence of 1 or more of the criteria including snoring, witnessed apnea or daytime sleepiness, and >5 apneahypopnea index (AHI) score identified on PSG. Obstructive sleep apnea syndrome severity based on AHI was mild for AHI = 5-15, moderate for AHI = 15-30, and severe for AHI >30.[10]

Statistical Analysis

Shapiro–Wilk test was used for suitability with normal distribution. Student’s t-test was used to compare normally distributed features in 2 independent groups. Mann–Whitney U-test was used to compare non-normally distributed properties. Relationships between numerical variables were tested with Pearson’s correlation coefficient. Mean ± standard deviation values were given for numerical variables as descriptive statistics. Number and percent values were given for categorical variables. Statistical Package for the Social Sciences software Windows version 23.0 package program was used for statistical analysis and P < .05 was considered statistically significant.

Results

Of the 49 SCD patients evaluated for our study, 28 patients who gave consent to participate in the study, who were not in a painful crisis attack, and who had sufficient sleep efficiency as a result of polysomonographic evaluation were included in the study. Of the 30 healthy volunteers who were evaluated in the control group, 22 individuals who had no comorbidity and gave consent to participate in the study were included in the study. There were a total of 28 patients in the SCD group including 16 males (57.1%) and 12 females (42.9%). In the control group, there were a total of 22 patients, 13 men (59.1%) and 9 women (40.9%). Both groups were similar in terms of gender (P = .890). Both groups were similar in terms of mean age (32.96 ± 8.31 in SCD patients and 35.23 ± 9.40 for the control group) and BMI (22.31 ± 3.57 in SCD patients and 23.94 ± 2.79 in the control group, respectively; P = .371, P = .084, respectively) ) (Table 2).
Table 2.

Comparison of Age, Gender, and BMI of groups

Sickle Cell Disease Patient Group (n = 28)Control Group(n = 22) P
Age (mean ± SD)32.96 ± 8.3135.23 ± 9.40.371
BMI (mean ± SD)22.31 ± 3.5723.94 ± 2.79.084
Gender (n, %) Female Male 12 (42.9%)16 (57.1%) 9 (40.9%)13(59.1%) .890

BMI, body mass index; SD, standard deviation.

The total ESS score was statistically higher in the SCD patient group than in the control group (ESS was 5.71 ± 3.48 in SCD patients and 3.00 ± 3.27 in the control patient group, P = .001). When the Berlin Sleep Questionnaire and Stanfort Sleepiness Scale results were compared between the control group and the SCD patient group, the results of both scales were found to be significantly higher in the SCD patient group (P-values: .008-.002, respectively). The polysomnographic evaluation results of both groups are given in Table 3. While sleep efficiency was 72.94 ± 11.32 in the SCD group, it was 88.94 ± 8.12 in the control group and sleep efficiency was significantly lower in SCD patients (P < .001). While the minimum oxygen saturation during sleep was 84.14 ± 5.1 in the SCD patient group, it was 91.32 ± 5.59 in the control group. Hence, the minimum saturation at night was significantly lower in the SCD group than in the control group (P < .001). Stage 3 sleep percentage was found to be significantly lower in the SCD patient group compared to the control group (P = .023). However, the percentage of sleep stage 1, supine/non-supine AHI, and rapid eye movement (REM)/non-REM AHI were found to be significantly higher in the SCD group than in the control group.
Table 3.

Comparison of Polysomographic Data

Sickle Cell Disease Patient Group (n = 28) (Mean ± SD)Control Group(n = 22) (Mean ± SD) P
Sleep efficiency72.94 ± 11.3288.94 ± 8.12<.001*
Stage 1 %8.37 ± 6.095.04 ± 3.9 .036*
Stage 2 %54.24 ± 13.9360.7 ± 10.82.080
Stage 3 %11.07 ± 6.6216.63 ± 10.1 .023*
REM%10.27 ± 7.313.75 ± 7.13.080
AHİ17.47 ± 17.843.44 ± 3.67<.001*
Supin AHİ21.42 ± 25.43.21 ± 4.28<.001*
Nonsupin AHİ10.29 ± 13.412.88 ± 3.98 .014*
Rem AHİ19.74 ± 28.354.33 ± 5.53 .029*
Non-REM AHİ15.24 ± 18.013.22 ± 3.73<.001*
Minimum saturation84.14 ± 5.191.32 ± 5.59<.001*
Mean saturation93.95 ± 2.8192.61 ± 18.72 .001*
ODI11.34 ± 13.680.83 ± 1.18<.001*
PLMI2.35 ± 3.080.6 ± 1.48 .002*
Minimum heart rate51.96 ± 6.1447.86 ± 4.82 .013*
Mean heart rate65.89 ± 7.3562.82 ± 5.78.114
Maximum heart rate97.18 ± 10.78100.85 ± 2.31 .014*
OSAS (n, %) Mild Moderate Severe 8 (28.6%)9 (36.1%)4 (14.3%) 5 (22.7% )0 (0%)0 (0%) .001*
IRLS-RS (n, %) Mild  Moderate  Severe  Very severe 12 (44%)7 (25%)7 (25%)1 (3%) 0 (0%)1 (3%)0 (0%)0 (0%) .001*
Johns Hopkins RLS (n, %)  Mild  Moderate Severe 13 (48%)9 (9%)5 (18%) 1 (3%)0 (0%)0 (0%) .001*

AHI, apnea–hypopnea index; ODI, oxygen desaturation index; PLMI, periodic leg movement index; IRLS-RS, International Restless Leg Syndrome Rating Scale; RLS, restless leg syndrome.

*P < .05 was considered statistically significant

When the apnea–hypopnea index was examined, it was found to be 17.47 ± 17.84 in the SCD group and 3.44 ± 3.67 in the control group. The AHI level in the SCD group was found to be statistically significantly higher than the control group (P < .001). Oxygen desaturation index (ODI) was significantly higher in the SCD group (11.34 ± 13.68) compared to the control group (0.83 ± 1.18) (P < .001). In the SCD patient group, OSAS was detected in a total of 19 patients. Of these, 8 patients (28%) had mild OSAS, 7 patients (25%) had moderate OSAS, and 4 patients had severe OSAS. In the control group, OSAS was detected in 5 patients (22%), and all patients had mild OSAS. In the SCD group, restrictive type respiratory dysfunction was found in 11 patients (39%) and mixed (obstructive + restrictive) type respiratory dysfunction was detected in 1 patient (3%). The mean forced expiratory volume in 1 second (FEV1%) and forced vital capacity (FVC%) values were significantly lower in the SCD group than in the control group (P = .004, P = .007, respectively) (Table 4). When the correlation between pulmonary function tests and ODI and AHI was examined, it was found that there was a weak negative correlation between AHI and ODI as the FEV1 level decreased in patients (r = −0.314; r = −0.276, respectively), but no significant correlation was found with FVC. A moderate positive correlation was found between FEV1 and FVC values and minimum saturation (r values were 0.437 and 0.413, respectively).
Table 4.

Pulmonary function test results

Sickle Cell Disease Patient Group (n = 28) (mean ± SD)Control Group(n = 22) (mean ± SD) P
FEV1%74.54 ± 1388.82 ± 20.08 .004*
FVC%75.61 ± 13.5389.5 ± 21.14 .007*
FEV1/FVC84.2 ± 4.584.17 ± 5.28.984

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.*P < .05 was considered statistically significant

When the periodic leg movement index (PLMI) of the groups were compared, PLMI was found to be 2.35 ± 3.08 in the SCD patient group and 0.6 ± 1.48 in the control group, and it was significantly higher in the SCD patient group (P = .002). When the groups were compared in terms of RLS, 27 patients in the SCD group and 1 patient in the control group were accepted as RLS according to the IRLSSG criteria. According to IRLSSG Severity Scale (IRLSSG-SS), in the SCD group, 12 patients (44%) had mild, 7 patients (25%) had moderate, 7 patients (25%) had severe, and 1 patient (3%) had very severe RLS. In the control group, moderate RLS was detected in 1 patient. When the JHRLSS was evaluated, of the 27 patients with RLS, 13 (48%) had mild RLS, 9 patients (9%) had moderate severity, and 5 patients (18%) had severe RLS. One patient in the control group with RLS symptoms had mild RLS symptoms. In the SCD patient group, it was reported that the patients were admitted to the emergency department on an average of 3.03 ± 2.5 times in the last year due to an attack (venoocclusive crisis or acute chest syndrome) (min: 0; max: 10). It was also determined that the patients had an average of 1.2 ± 1.2 (min: 0; max: 4) hospitalizations in the last 1 year. When the SCD patient group was evaluated within itself, it was found that as AHI increased, sleep efficiency decreased in moderate and statistically significant (r = −0.401, < .05). A very strong positive correlation was found between the AHI level and the patients’ admission to the emergency service due to vasoocclusive crisis and/or acute chest syndrome in the last 1 year (r = 0.805, P < .01). In other words, as the AHI increased, the emergency admissions of the patients increased significantly. A statistically significant positive correlation was found between the AHI and the number of hospitalizations of the patients in the last 1 year (r = 0.657, P < .01). The correlation between sleep parameters in the SCD patient group and attacks and hospitalizations in the last 1 year is shown in Table 5. The scatter plots graph of the correlation between AHI and the number of admissions to the emergency department and the number of hospitalizations due to an attack in the last 1 year are shown in Figures 1A and 1B.
Table 5.

Correlation Analysis Between Sleep Data and Attacks and Hospitalizations in Sickle Cell Disease Patients (r values)

AHIMinimum SaturationMean SaturationAttackHospitalitazion
ODI0.961** −0.525** −0.0280.733** 0.584**
AHI −0.546** −0.0190.805** 0.657**
Minimum saturation −0.001−0.496** −0.354
Mean saturation −0.2520.005
Attack 0.834**

**Correlation is significant at the 0.01

*Correlation is significant at the 0.05

ODI, oxygen desaturation index; AHI, apnea–hypopnea index.

Figure 1.

A. Scatter plots graph of the correlation between AHI and hospitalizations. B. Scatter plots graph of the correlation between AHI and the number of admissions to the hospital in the last 1 year due to attack. AHI, apnea–hypopnea index.

As AHI increased in SCD patients, the patients had more severe RLS symptoms. A positive moderate statistically significant correlation was found between AHI and IRLSSG-SS (r = 0.469, P < .01). Restless leg syndrome symptoms were more severe in patients with higher AHI values. A moderate statistically significant negative correlation was found between the minimum oxygen saturation during night sleep and the number of emergency admissions within the last 1 year (r = −0.496, P < .05). However, a weak negative correlation was found between minimum saturation and the number of hospitalizations in the last 1 year (r = −0.354).

Discussion

In this study, the frequency of OSAS in SCD patients and SCD prognosis in patients with OSAS were evaluated. In our study, OSAS was detected in 19 patients (67%) after polysomnographic evaluation in the SCD patient group. This number was significantly higher than the control patient group. Similar to our study, Wallen et al[11] evaluated the Pittsburgh Sleep Quality Index questionnaire in terms of accompanying sleep disorders in 328 adult SCD patients, patients with a score of 5 and above were defined as having sleep disorders, and they found sleep disturbances in more than 70% of adults with SCD. Sharma et al[12] performed a comprehensive sleep assessment and polysomnography at an accredited sleep center on 32 adult SCD patients with irregular sleep or patients with ESS score of ≥10 and found that the prevalence of sleep breathing disorder in these patients was 44%. They found that the severity of the disease was generally mild and moderate (mean AHİ = 17/h (95% CI: 10-24/h)) and they also found that 57% of the patients were accompanied by sleep disorders such as insomnia and delayed sleep phase syndrome.[12] In our study, 8 (28%) of the patients with OSAS in the SCD patient group had mild OSAS, 7 (25%) had moderate OSAS, and 4 had severe OSAS. In another study, Berlin Sleep Questionnaire was applied to 47 patients who were followed up with a diagnosis of SCD and they performed polysomnographic evaluations in 13 patients who were considered to be high risk for OSAS, and they found OSAS in 23% of the patients.[13] In our study, 6 patients who underwent the Berlin Sleep Questionnaire were found to be at high risk for OSAS, and 4 of these 6 patients had severe OSAS and 2 of them had moderate OSAS. In 10 patients included in the study, at least 2 categories were evaluated as positive in the Berlin Sleep Questionnaire, and moderate OSAS was found in 7 of these patients and mild in 3 of them. In many studies of patients with SCD, hypoxia was observed during the day, while sleeping or after exercising. The results of this hypoxia occurring in children and adult patients with SCD are not clear. In some studies, hypoxia is accepted as a high risk for cognitive impairment, especially in children, while it is considered a risk for more pain attacks and secondary pulmonary complications (such as pulmonary hypertension) in adults.[14] In our study, in the SCD patient group, the minimum oxygen saturation values observed at night and the average oxygen saturation values detected during sleep were found to be significantly lower than the control group. In a study conducted by Rosen et al[15], in which 243 SCD children (mean age 10) were evaluated, they found that children with SCD experienced more nighttime desaturation and, beyond this, the prevalence of sleep breathing disorders compatibility with OSAS was higher.[15] When Kaleyias et al[16] compared children with SCD to healthy controls, they found that the oxygen saturation rate below 85% was 4 times higher in children with SCD. They also found more severe nocturnal desaturation and hypercapnia in children with SCD with suspected OSAS compared to children with OSAS without complications.[16] In another similar study, night desaturation was found more frequently in the SCD group than in the control group, and the median SpO2 and minimal SpO2 were significantly lower in the SCD group.[17] Spivey et al[18] showed that SCD children with a daytime saturation SpO2 ≤94% are a reasonable threshold for screening for sleep breathing disorders. They found abnormal sleep patterns in all 12 SCD children with a daytime SpO2 94%. They also found OSAS in 35% of these children. Many studies have found that as the depth of hypoxemia increases, complications associated with SCD increase. Patients presented with more pain and more frequent acute chest syndrome clinic. Especially in children, neurocognitive functions were impaired. In our study, as the degree of OSAS increased and the minimum oxygen saturation during sleep decreased, the emergency admissions of the patients in the last 1 year increased significantly, and a significant increase was found in hospitalizations due to vasoocclusive crisis and/or acute chest syndrome in the last 1 year. In SCD patients, hypoxia that deepens more at night contributes to the polymerization of Hb S, which has been found to lead to more vaso-occlusion and other complications.[19] Also, Katz et al[20] in their study found higher rates of pneumonia, cardiovascular, and neurological complications in children with OSAS and SCD compared to children with SCD without OSAS. In a study by Narang et al[21], it was evaluated whether the use of hydroxyurea (HU) was associated with a decrease in the frequency of OSA and high nocturnal and awake oxygen saturation (SaO2) in children with SCD. Hydroxyurea use was associated with an increase in alertness and nocturnal SaO2, although there was no difference in the severity of obstructive apnea–hypopnea index. It has been emphasized that improving night SaO2 can be an important mechanism of action of HU treatment.[21] Because all of our patients used HU, the efficiency of HU could not be evaluated. In studies, restrictive type respiratory dysfunction has been found especially in adults with SCD, while obstructive type disorders have been detected in children and adolescents.[22,23] Possible factors associated with restrictive respiratory dysfunction in SCD patients are acute or chronic inflammation and resulting fibrosis, recurrent episodes of acute chest syndrome, small vessel vascular volume on computed tomography sections, cardiomegaly, and pulmonary hypertension.[24] In our study, restrictive type respiratory dysfunction was common in the SCD patient group, and as the FEV1 level decreased in these patients, ODI and AHI levels increased significantly. However, secondary causes of restrictive pathology were not investigated in our patients. Since higher AHI levels are detected in patients with restrictive respiratory dysfunction, we think that OSAS symptoms should be questioned, especially in these patients, and PSG should be performed if necessary, regardless of the presence of symptoms. Another condition that can affect the sleep quality of SCD patients is RLS, which affects 8.4% of the general population. Wali et al[25] in their study in which they evaluated 44 patients with SCD and 45 patients with non-SCD anemia found higher RLS rates and lower sleep quality in patients with SCD.[25] Rogers et al[26] evaluated the frequency and rates of PLM in 64 children with sickle cells aged 2-18 years. They found the average PLM index in children to be 3.7. They found RLS in 12.5% of the children. And in these children, accompanying sleep disorders were found to be more frequent and sleep efficiency was lower. In another study, 36% of adolescent SCD patients had sleep breathing disorders and 23% of these patients had PLM. Again, in the same study, 21%- 41% of adolescent with SCD reported a behavioral sleep disorder characterized by insomnia, difficulty in falling asleep, and maintaining sleep.[27] Similarly in our study, very high levels of RLS were found in the SCD group compared to the control group according to the criteria of the IRLSSG. Restless leg syndrome symptoms were especially detected in moderate and severe levels. Again, significantly lower sleep efficiency and more disturbances in sleep quality were found in the SCD group than in the control group.

Conclusion

Obstructive sleep apnea syndrome is a treatable condition that can have adverse health consequences, and studies have found that it is more common in patients with SCD. Therefore, in this high-risk SCD patient population, we think that performing and evaluating procedures for screening, diagnosis, and treatment of OSAS will improve the patient’s quality of life in preventing complications and improving sleep quality. Therefore, all SCD patients should be evaluated for OSAS. Also, we think that PSG should be performed on patients with OSAS symptoms, frequent attacks, frequent hospitalization rates, and restrictive respiratory dysfunction.
  23 in total

1.  Obstructive sleep apnea and sickle cell anemia.

Authors:  Carol L Rosen; Michael R Debaun; Robert C Strunk; Susan Redline; Sinziana Seicean; Daniel I Craven; Johanna C D Gavlak; Olu Wilkey; Baba Inusa; Irene Roberts; R Lucas Goodpaster; Beth Malow; Mark Rodeghier; Fenella J Kirkham
Journal:  Pediatrics       Date:  2014-07-14       Impact factor: 7.124

2.  Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.

Authors:  Indra Narang; Gili Kadmon; Dennison Lai; Simranpal Dhanju; Melanie Kirby-Allen; Isaac Odame; Reshma Amin; Zihang Lu; Suhail Al-Saleh
Journal:  Ann Am Thorac Soc       Date:  2015-07

3.  Effects of adenotonsillectomy on polysomnographic parameters in children with sickle cell disease.

Authors:  Paul Finch; Rose Mary Stocks; Matthew P Smeltzer; Amy Kimble; Robert Schoumacher; Jane S Hankins
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

4.  Sleep pathology characterization in sickle cell disease: case-control study.

Authors:  Maria Inês Mascarenhas; Helena Cristina Loureiro; Teresa Ferreira; Alexandra Dias
Journal:  Pediatr Pulmonol       Date:  2014-07-10

5.  Sleep Problem Risk for Adolescents With Sickle Cell Disease: Sociodemographic, Physical, and Disease-related Correlates.

Authors:  Cecelia R Valrie; Krystal L Trout; Kayzandra E Bond; Rebecca J Ladd; Nichelle L Huber; Kristen J Alston; Alicia M Sufrinko; Erik Everhart; Beng R Fuh
Journal:  J Pediatr Hematol Oncol       Date:  2018-03       Impact factor: 1.289

Review 6.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

7.  Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.

Authors:  Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

8.  Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease.

Authors:  P L Whitesell; O Owoyemi; P Oneal; M Nouraie; E S Klings; A Rock; T A Mellman; T Berihun; J Lavella; R E Taylor; S P Perrine
Journal:  Sleep Med       Date:  2016-06-23       Impact factor: 3.492

9.  Restless legs syndrome and sleep quality among adult sickle cell disease patients.

Authors:  Siraj Omar Wali; Ibrahim AlQassas; Roah Merdad; Rajaa Alsaggaf; Fatin Al-Sayes
Journal:  Sleep Breath       Date:  2017-11-19       Impact factor: 2.816

10.  Severity of obstructive sleep apnea in children with sickle cell disease.

Authors:  Joseph Kaleyias; Navid Mostofi; Mitzie Grant; Camille Coleman; Lori Luck; Carlton Dampier; Sanjeev V Kothare
Journal:  J Pediatr Hematol Oncol       Date:  2008-09       Impact factor: 1.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.